BGC > Product Search > Acalabrutinib

Description :
Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. It inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway.

• Molecular Weight :465.52
• Purity :> 98%

Molecular Formula :
C26H23N7O2
Canonical SMILES :
CC#CC(=O)N1CCCC1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5
InChI :
InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1
InChIKey :
WDENQIQQYWYTPO-IBGZPJMESA-N
Solubility :
Soluble in DMSO.
Appearance :
White to Off-white Solid
Storage : Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -20℃ for long term (months to years).
Synonyms :
ACP-196; ACP196; ACP 196; Acalabrutinib; 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide

More details are to be found here